Share on StockTwits

Bioline RX (NASDAQ:BLRX) announced its earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.10, Analyst Ratings Network reports.

Bioline RX (NASDAQ:BLRX) opened at 2.02 on Tuesday. Bioline RX has a one year low of $1.55 and a one year high of $3.34. The stock has a 50-day moving average of $2.08 and a 200-day moving average of $2.55. The company’s market cap is $68.4 million.

A number of research firms have recently commented on BLRX. Analysts at Maxim Group raised their price target on shares of Bioline RX from $4.00 to $7.00 in a research note on Thursday, May 8th. They now have a “buy” rating on the stock. On the ratings front, analysts at B. Riley initiated coverage on shares of Bioline RX in a research note on Friday, April 25th. They set a “buy” rating and a $4.00 price target on the stock.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.